The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...
The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...
A total of 5,919 patients diagnosed with invasive breast cancer were analyzed ... and 57.6% of the cohort were ER/PR+, HER2– (which includes ER+/PR+, HER2–; ER–/PR+, HER2–; ER+/PR–, HER2–). Nearly ...
The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with ...
A MUM has shared a shocking photo of a giant lump protruding from her breast, which doctors repeatedly dismissed a benign. But after months of being told there was nothing to worry about, Tirzah ...
Receiving a diagnosis of HER2+ and ER+ breast cancer that has spread or cannot be surgically removed can feel overwhelming, but understanding the condition and your options can help you navigate this ...
The EMBER-3 trial demonstrated the effectiveness of imlunestrant, both as monotherapy and in combination with abemaciclib, in patients with ESR1-mutated oestrogen (ER ...
Overall survival outcomes for breast cancer brain metastasis patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback